Search Results - "Spazzapan, S"

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT by Regan, M.M., Walley, B.A., Francis, P.A., Fleming, G.F., Láng, I., Gómez, H.L., Colleoni, M., Tondini, C., Pinotti, G., Salim, M., Spazzapan, S., Parmar, V., Ruhstaller, T., Abdi, E.A., Gelber, R.D., Coates, A.S., Goldhirsch, A., Pagani, O.

“…Recent breast cancer treatment guidelines recommend that higher-risk premenopausal patients should receive ovarian function suppression (OFS) as part of…”
Get full text

Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy by Muraro, E, Comaro, E, Talamini, R, Turchet, E, Miolo, G, Scalone, S, Militello, L, Lombardi, D, Spazzapan, S, Perin, T, Massarut, S, Crivellari, D, Dolcetti, Riccardo, Martorelli, D

“…Locally advanced HER2-overexpressing breast cancer (BC) patients achieve a high rate of pathological complete responses (pCR) after neoadjuvant chemotherapy…”
Get full text

Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) by Spazzapan, S, Conte, P, Simoncini, E, Campone, M, Miller, M, Sonke, G

Get full text

Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer by Cortes, J., Perez-Garcia, J., Levy, C., Gómez Pardo, P., Bourgeois, H., Spazzapan, S., Martínez-Jañez, N., Chao, T.-C., Espié, M., Nabholtz, J.M., Gonzàlez Farré, X., Beliakouski, V., Román García, J., Holgado, E., Campone, M.

“…There is no standard treatment after progression on second-line chemotherapy for metastatic breast cancer (MBC). We compared vinflunine with physician’s choice…”
Get full text

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer by Gori, S., Montemurro, F., Spazzapan, S., Metro, G., Foglietta, J., Bisagni, G., Ferzi, A., Silva, R.R., Gamucci, T., Clavarezza, M., Stocchi, L., Fabi, A., Cognetti, F., Torrisi, E., Crivellari, D.

“…Preclinical data suggest that treatment with lapatinib reinduces sensitivity to trastuzumab in human epidermal growth factor receptor 2(HER2)-positive breast…”
Get full text

Five Year Results With 3-D Conformal Radiation Therapy to Deliver Partial-Breast Irradiation Consisting of 40 Gy in 10 Daily Fractions by Trovo, M, Piccoli, E, Micheli, E, Mileto, M, Favaro, A, Perin, T, Spazzapan, S, Massarut, S, Roncadin, M

Get full text

Stereotactic Ablative Radiation Therapy (SABR) for Oligometastatic Breast Cancer Patients: Investigating the Immune Profile to Identify Predictive Biomarkers by Muraro, E, furlan, C, Berretta, M, Militello, L, Del Conte, A, Spazzapan, S, Comaro, E, Dolcetti, R, Trovo, M

Get full text

PO-0675: Radical radiotherapy in ologometastatic breast cancer patients by Trovo, M, Furlan, C, Berretta, M, Militello, L, Spazzapan, S, Polesel, J, Del Conte, A, Arcangeli, S, Fiorentino, A, Franchin, G

Get full text

Cancer and aging: are there any differences in the information needs of elderly and younger patients? Results from an Italian observational study by Giacalone, A., Blandino, M., Spazzapan, S., Tirelli, U.

Get full text

Fatigue in cancer patients receiving chemotherapy: an analysis of published studies by Spazzapan, S., Bearz, A., Tirelli, U.

Get full text

Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors by Minisini, A., Spazzapan, S., Crivellari, D., Aapro, M., Biganzoli, L.

“…There is concern about the potential increase of hematological toxicity in elderly patients treated with chemotherapy. Recently, primary prophylaxis with…”
Get full text

Gefitinib in patients with non-small cell lung cancer: Symptomatic improvement within a few days by Bearz, A., Vaccher, E., Spazzapan, S., Berretta, M., Tirelli, U.

Get full text

Use of sorafenib in elderly patients (EP) affected by metastatic renal cell carcinoma (RCC) according to the Comprehensive Geriatric Assessment (CGA) by Fratino, L, Simonelli, C, Giacalone, A, Nigri, P, Sartor, I, Tartuferi, L, Tedeschi, R, Steffan, A, Talamini, R, Spazzapan, S, Berretta, M, Vaccher, E, Tirelli, U

Get full text

Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma by Simonelli, C., Talamini, R., Bearz, A., Berretta, M., Spazzapan, S., Monini, P., Sgadari, C., Sartor, I., Ensoli, B., Tirelli, U.

Get full text

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer by Francis, Prudence A, Pagani, Olivia, Fleming, Gini F, Walley, Barbara A, Colleoni, Marco, Láng, István, Gómez, Henry L, Tondini, Carlo, Ciruelos, Eva, Burstein, Harold J, Bonnefoi, Hervé R, Bellet, Meritxell, Martino, Silvana, Geyer, Charles E, Goetz, Matthew P, Stearns, Vered, Pinotti, Graziella, Puglisi, Fabio, Spazzapan, Simon, Climent, Miguel A, Pavesi, Lorenzo, Ruhstaller, Thomas, Davidson, Nancy E, Coleman, Robert, Debled, Marc, Buchholz, Stefan, Ingle, James N, Winer, Eric P, Maibach, Rudolf, Rabaglio-Poretti, Manuela, Ruepp, Barbara, Di Leo, Angelo, Coates, Alan S, Gelber, Richard D, Goldhirsch, Aron, Regan, Meredith M

“…At 8 years of follow-up, premenopausal women with breast cancer had higher rates of disease-free and overall survival with the addition of ovarian suppression…”
Get full text

Ifosfamide in advanced/disseminated breast cancer by Sorio, R, Lombardi, D, Spazzapan, S, La Mura, N, Tabaro, G, Veronesi, A

“…Ifosfamide is an alkylating agent active in various tumor types including breast cancer. The availability of mesna (sodium 2-mercaptoethanesulfonate) has…”
Get more information

242P Investigating the risk of drug-induced interstitial lung disease in patients with metastatic breast cancer treated with antiHER2 regimens through a network meta-analysis approach by Palmero, L., Siciliano, M.A., Di Nardo, P., Basile, D., Cucciniello, L., Pastò, B., Lisanti, C., Membrino, A., Noto, C., Spazzapan, S., Gerratana, L., Puglisi, F.

Get full text

458P Metastatic breast cancer: How and how often do we communicate? Results from an Italian national survey by Lisanti, C., Costantini, A., Pastò, B., Garutti, M., Bolzonello, S., Da Ros, L., Di Nardo, P., Corsetti, S., Gerratana, L., Scalone, S., Spazzapan, S., Nicoloso, M.S., Della Rossa, S., Rizzetto, M., Membrino, A., Cinieri, S., Bonifacino, A., Puglisi, F.

Get full text

Treatment of older breast cancer patients with high recurrence risk by Crivellari, D., Spazzapan, S, Lombardi, D, Berretta, M, Magri, M.D, Sorio, R, Scalone, S, Veronesi, A

“…Adjuvant treatment of elderly women affected by breast cancer who have a high risk of recurrence is one of the most questionable issues in clinical oncology…”
Get full text

249P A retrospective analysis on capecitabine and vinorelbine combination in metastatic breast cancer: The MARCELLINO study by de Scordilli, M., Bortot, L., Cucciniello, L., Totaro, F., Mazzeo, R., Alberti, M., Palmero, L., Targato, G., Dri, A., Pravisano, F., Zapelloni, G., Lisanti, C., Spazzapan, S., Minisini, A.M.M., Mansutti, M., Bonotto, M., Gerratana, L., Fasola, G., Puglisi, F.

Get full text